Related Experiment Video

Updated: Aug 24, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A new therapeutic antibody masks ErbB2 to its partners

Ali Badache1, Nancy E Hynes

  • 1Friedrich Miescher Institute of the Novartis Research Foundation, P.O. Box 2543, CH-4002 Basel, Switzerland.

Cancer Cell
|April 20, 2004
PubMed

Insights

Pertuzumab antibody targets ErbB2 receptor tyrosine kinase, preventing cancer cell dimerization. This offers new therapeutic options for ligand-activated ErbB2 tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Structural Biology

Background:

  • ErbB2 receptor tyrosine kinase activation in cancer occurs via overexpression or ligand-mediated dimerization.
  • Trastuzumab targets overexpressed ErbB2 in metastatic breast cancer.
  • Pertuzumab offers a novel therapeutic strategy by inhibiting ligand-induced ErbB2 dimerization.

Discussion:

  • Pertuzumab's mechanism involves preventing ErbB2 from forming dimers with other ErbB receptors.
  • This differs from trastuzumab, which targets overexpressed ErbB2.
  • Structural insights reveal how pertuzumab disrupts ligand-induced ErbB2 activation.

Key Insights:

  • Pertuzumab inhibits ligand-induced ErbB2 dimerization, a distinct mechanism from trastuzumab.
  • Structural study elucidates pertuzumab's interaction with ErbB2.
  • This provides a basis for treating cancers with ligand-activated ErbB2.

Outlook:

  • Pertuzumab may provide new treatment avenues for ErbB2-driven cancers.
  • Further research can explore combination therapies involving pertuzumab.
  • Understanding ErbB2 signaling pathways is crucial for targeted cancer therapy.

More Related Videos

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cross-reactivity00:42

Cross-reactivity

Overview
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...